While the clinical benefit of current HEMT is beyond dispute, in the long-term, our results may help in guiding the development of the next generation of CFTR correctors that correct CFTR folding/trafficking while not targeting KCa channels, thus further improving the lives of patients with CF. The gene discussed is CFTR; the disease is cystic fibrosis.